Expanded Access for PSV Personalized Oncolytic Viruses (PSV)
Sponsor: EpicentRx, Inc.
This observational or N/A phase trial investigates Cancer and is currently ongoing. EpicentRx, Inc. leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Apr 2019 — Jan 2021 [monthly]
No Longer Available
-
Jun 2018 — Apr 2019 [monthly]
No Longer Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- EpicentRx, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.